Table 4. Activity of Representative Compounds against Clinical Isolates of M. tuberculosis.
| MIC (μg/mL) |
|||||
|---|---|---|---|---|---|
| compounds | H37Rv | 13946a | 14862b | PBTZ169-resistant strain | bedaquiline-resistant strain |
| 23j | 0.055 | 0.082 | 0.059 | 0.14 | |
| 24f | 0.020 | 0.031 | 0.031 | 0.062 | 0.054 |
| 24j | 0.059 | 0.12 | 0.12 | ||
| 24k | 0.15 | 0.44 | 0.23 | ||
| 25a | 0.12 | 0.24 | 0.24 | 0.48 | |
| 25b | 0.030 | 0.062 | 0.12 | ||
| 25l | 0.20 | 0.94 | 0.48 | ||
| TCA1 | 0.47 | 0.95 | 0.48 | 1.23 | |
| INH | 0.019 | 2.46 | >10 | ||
| RFP | 0.015 | >10 | 9.24 | ||
| PBTZ169 | 0.0001 | 0.005 | |||
| bedaquiline | 0.036 | 2.24 | |||
a
Resistance to isoniazid (INH), streptomycin (SM), rifampicin (RFP), ethambutol (EMB), rifabutin (RBT), paza-aminosalicylate (PAS), and ofloxacin (OFLX).
b
Resistance to INH, SM, RFP, EMB, PAS, prothionamide (1321), and capreomycin (CPM).